Top Markets
#1 Black Phoenix Black Phoenix +350.66%
#2 Islamic Coin Islamic Coin +158.09%
#3 Glidr Glidr +58.56%
#4 Cryptopia Cryptopia +20.42%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.26%
#6 DOVU DOVU +16.40%
#7 Pons Pons +8.78%
#8 stake.link stake.link +8.32%
#9 COTI COTI +6.82%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +6.08%
Coin of the day
Black Phoenix Black Phoenix
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.

Samsung Biologics Co.,Ltd.

207940
Kedudukan dalam Saham #513
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon,... Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
Harga Saham
$1,073.54
Modal Pasaran
$49.70B
Perubahan (1 hari)
0.23%
Perubahan (1 tahun)
-7.37%
Negara
KR
Perdagangan Samsung Biologics Co.,Ltd. (207940)

Kategori

Healthcare
Pendapatan untuk Samsung Biologics Co.,Ltd. (207940)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Samsung Biologics Co.,Ltd., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Samsung Biologics Co.,Ltd. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU